Daiichi Sankyo Reports First patient Dosing in P- I/II Trial of DS-1594 to Treat Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia

April 8, 2021 Auto Bot acute myeloid leukemia, Clinical Trials, Daiichi Sankyo, Dosing, First, Patient, reports, Treat 0

Shots:

  • MD Anderson will sponsor and lead P-I/II study to assess DS-1594 as monothx. and in combination regimens for patients with r/r AML and ALL
  • The 1EPs of the P-I part of the study is to determine the maximum tolerated dose and RP2D of DS-1594 in ~54 patients with AML or ALL regardless of mutation status. The 2EPs include CR and CR with CRh
  • The P-II part of the study will evaluate DS-1594 at the established dose in four expansion cohorts of patients with specific genetic markers. The study enrolled ~170 patients which will initially be conducted only at MD Anderson with global expansion planned for P-II

Click here to­ read full press release/ article | Ref: BusinessWire | Image: The Japan Times

The post Daiichi Sankyo Reports First patient Dosing in P- I/II Trial of DS-1594 to Treat Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia first appeared on PharmaShots.